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Properdin factor D,1 a 23,500 tool wt euglobulin (6), interacts with properdin 
factor B  and cobra venom factor (CoVF) to generate the CoVF-dependent C3 
convertase which cleaves C3  (7)  and activates the terminal  complement com- 
ponents,  C5-C9  (8).  Fluid  phase  C3b,  the  major  cleavage  fragment  of  C3, 
interacts with factors B  and D  in a manner analogous to CoVF to form a fluid 
phase  C3b-dependent  C3  convertase  (4).  More  recently,  C3b  bound  to  a 
sheep erythrocyte has been shown to react with factors B  and D  to generate  a 
cell-bound C3b-dependent  C3 convertase,  EAC43B(D), which, like the classi- 
cal cellular intermediate,  EAC142, activates C3-C9 to bring the lytic sequence 
to completion  (9).  In the present study, factor D  is shown to be inhibited  by 
diisopropylphosphofluoridate  (DFP)  and  derived  from a  previously  unrecog- 
nized DFP-resistant precursor protein of similar molecular weight. 
Materials and Methods 
Crude, lyophilized cobra venom (Ross Allen's Reptile Institute, Inc., Silver Springs, Fla.), 
hexadimethrine bromide and DFP (Aldrich Chemical Co., Inc., Milwaukee, Wis.), Enzodif- 
fusion  fibrin  plates  and  streptokinase  (Hyland  Div.,  Travenol  Laboratories,  Inc.,  Costa 
Mesa, Calif.), tosyl-L-lysine chloromethyl ketone (TLCK)  (Cyclo Chemical Div. of Travenol 
Laboratory, Costa Mesa, Calif.), crystalline  trypsin  and soybean  trypsin  inhibitor  (SBTI) 
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1  The nomenclature  for classical complement components conforms to that agreed upon 
under the auspices of the World Health Organization (1968. Bull. W. tt. O. 39:395). Properdin 
factor B is synonymous with C3 proactivator  (1, 2) and glycine-rich beta glycoprotein (3); 
factor D is synonymous with C3 proactivator  convertase  (4) and GBGase (5). The cellular 
intermediate  bearing the C3b-dependent C3 convertase is represented  by EAC43B(D);  the 
parenthesis are placed about factor D to indicate that its presence in the intermediate  is not 
established. Other abbreviations used in this paper: C-EDTA, rat serum diluted 1  : 15 in  GVB- 
EDTA; CoVF, cobra venom factor; DFP,  diisopropylphosphofluoridate; DGVB  ++, Veronal- 
bufered saline with dextrose; GVB-EDTA, Veronal-buffered saline containing 0.04M EDTA; 
QAE, quaternary aminoethyl;  SBTI, soybean trypsin inhibitor;  TLCK,  tosyl-L-lysinechlor- 
omethyl ketone; Z, the average number of hemolytic sites/cell. 
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(Worthington Biochemical Corp., Freehold, N. J.), UM-10 Diaflo ultrafiltration membranes 
(Amicon Corp., Lexington, Mass.), and Indubiose agarose for immunoelectrophoresis (Fisher 
Scientific Co., Pittsburg,  Pa.) were obtained as indicated. 
Quaternary aminoethyl (QAE) A-50 Sephadex (Pharmacia Fine Chemicals, Inc., Piscat- 
away, N. J.) was equilibrated with buffer containing 0.0035 M PO4, pH 8.0, and utilized for 
ion exchange chromatography.  Conductance was measured  at 0°C  and  expressed as milli- 
siemens (mS). Gel filtration was performed with Sephadex G-75 using 0.05 M Veronal-buffered 
saline, pH 7.5, 7.5 mS, containing 5 X  10  -4 M Mg  ++, 1.5 X  10-  4 M Ca  ++, and 250 gg gelatin/ 
ml. The elution volumes were calculated from the net weight of the fractions in preweighed 
tubes and the apparent molwt was estimated using as standards ovalbumin, chymotrypsinogen, 
and ribonuclease A (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.). 
Preparation of CoVF, Classical Complement Components, and Properdin Factors.--CoVF 
was prepared and assayed from crude cobra venom as previously described (6, 10). Properdin 
factors B  and  D  were isolated from fresh frozen citrated human plasma  (6). The factor B 
preparation  exhibited a  single line on alkaline disk gel electrophoresis, was free of C2 and 
other classical complement components by hemolytic assays,  and was quantitated by radial 
immunodiffusion  against  monospecific antibody  (11).  The factor D  preparation  contained 
86 #g protein/mi by Folin assay (12) with serum albumin as the standard, and was devoid of 
factor B and hemolytic C1 activity. The activated first component of guinea pig complement 
(13) and the human components, C2 (14) and C3 (15), were isolated and measured as described. 
The C3  preparation  demonstrated  a  single line on alkaline disk  gel electrophoresis.  Fluid 
phase C3b, prepared by treatment of purified C3 with EAC14oxy2 (16), contained 400  t~g/ml 
of C3b and no residual C3 hemolytic activity. Plasmin, obtained by streptokinase activation 
of plasminogen which had  been isolated by aflfiaaity chromatography  and  Sephadex  G-150 
gel filtration, was assayed by its lyric activity in fibrin agarose plates relative to that of a 
standardized preparation  (17,  18). 
Cellular Intermediates and Activity Determinations.--Low ionic strength  Veronal-buffered 
saline with dextrose (DGVB++),  pH 7.5, 3.75 mS, containing 5 X  10  -4 M Mg  ++, 1.5  X  10  -4 
M  Ca  ++, and 0.1% gelatin, and  Veronal-buffered saline containing 0.04  M  EDTA (GVB- 
EDTA) were used as diluents (13). 
Sheep erythrocytes in the state EAC43 were prepared as previously described (9): EAC14 
(19) were reacted with purified C2, 1,000 effective molecules/cell, and C3, 50 effective mole- 
cules/cell, and then incubated in GVB-EDTA for 120 rain at 37°C to yield the cellular inter- 
mediate EAC43, by decay of C2 and dissociation of CT. In the stoichiometric assay for factor 
B, EAC43 are incubated with factor D and dilutions of factor B to generate the EAC43B(D) 
intermediate, and then lysed by addition of a source of C3-C9 (9). In order to screen chro- 
matographic fractions for factor B activity 2.5  X  l0  s EAC43 and 2 ng factor D in one drop 
DGVB++  (0.025  ml) were incubated with one drop of serially diluted column fractions for 
30 min at 30°C in microtiter plates; the lyric reaction was brought to completion by addition 
of three drops of rat serum diluted 1:15 in GVB-EDTA (C-EDTA) and incubation for 60 rain 
at 37°C. The CI-I~ units of factor B present in each column fraction were expressed as the re- 
ciprocal of the dilution at which 50% hemolysis occurred. Immunoelectrophoresis was per- 
formed in 1.5% agarose, 0.025 M Veronal, 0.002 M EDTA, pH 8.4,  at  15 V/era for 20  min, 
and the precipitin lines developed with monospecific rabbit antihuman factor B. 
P...~SU~TS 
Functional Ckaracteristics of Properdin Factor D.-- 
Effective  molecule  titration:  The  quantitative  relationship  between  the 
amount of factor D  present and the number of effective hemolytic sites gener- 
ated during incubation  with EAC43 and factor B  is shown in Fig.  1.  Samples DOUGLAS  T. FEARON,  K. FRANK AUSTEN~ AND SHAIYN RUDDY  357 
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FIG. I. The average number of hemolytic sites/cell generated during incubation of EAC43 
and factor B with variable amounts of factor D. 
of 5  X  107 EAC43 and 0.03 gg factor B  in 0.5 ml DGVB  ++ were brought to 
final volumes of 1.0 ml by addition of variable amounts of factor D  in 0.5 ml 
DGVB  ++. Mter the reaction mixtures were incubated for 30 rain at 30°C, 1.5 
ml C-EDTA were added and incubation continued for 60 rain at 37°C. The 
extent of hemolysis was  determined  and  the  average number  of hemolytic 
sites/cell  (Z)  calculated.  The  relationship  between  the  average  number  of 
hemolytic sites/cell formed and the input of factor D  was linear in the range 
studied. 
Inhibition:  DFP and TLCK, inhibitors of enzymatic sites containing serine 
(20)  and histidine (21) residues, respectively, were examined for their abilities 
to inhibit factor D. Three reaction mixtures, each containing 4.0/zg factor D 
in 2 ml DGVB  ++ were treated with either buffer, DFP  (10  -3 M),  or TLCK 
(10  -2 M)  for 30 rain at 30°C. Mter dialysis for 10 h  against four changes of 
500 ml  DGVB  ++,  each  reaction mixture was  assayed for residual  factor D 
activity by effective molecule titrations. As shown in Fig. 2, DFP treatment 
of factor D  irreversibly inhibited  all  functional activity,  while  exposure to 
TLCK had no effect. That the TLCK was  active was  demonstrated by its 
capacity to reduce by more than 95 %  the fibrinolytic activity of a sample of 
plasmin in a parallel experiment. 
In contrast to factor D, the activities of factor B and cell-bound C3b in the 
formation of EAC43B(D), and that of EAC43B(D) in activating C3-C9 were 
not inhibited by treatment with DFP.  Samples of 0.03/zg of factor B  were 
exposed either to buffer or DFP,  10-  3 M,  for 30 min at 30°C, dialyzed, and 
assayed for residual hemolytic activity by effective molecule titration; no dif- 358  PROPERDIN FACTOR D: ACTIVE SITE AND  PRECLrRSOR FORM 
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FIG.  2. The effects on factor D  activity of DFP  (O--O),  TLCK  (0--0),  and  buffer 
(A--A).  Bar  graphs  indicate  the  fibrinolytic activity  of  plasmin  treated  similarly with 
TLCK or buffer. 
ference in factor B activity was observed between the buffer-treated and DFP- 
treated samples. 5  X  l0  T EAC43/ml and 5  X  107 EAC43B(D)/ml  were  ex- 
posed to DFP, 10-3M, for30 rain at 30°C and then washed in DGVB  ++. Their 
capacity to be lysed by incubation  with  factors B  and D  and  C-EDTA,  or 
C-EDTA  alone,  respectively, was  identical  to  that  of cellular intermediates 
exposed to buffer rather than to DFP. 
Precursor Form of Factor D.--The recognition that factor D  was susceptible 
to inactivation by DFP led to an examination of human plasma for a  DFP- 
resistant precursor form of the protein. Trypsin was selected as the activating 
agent because of its broad spectrum of activity in the proteolytic activation of 
proenzymes (22). A  25,000 mol wt fraction of serum proteins was used as the 
initial possible source of substrate because active factor D  resides with mole- 
cules of this size. 
Trypsin-inducible  factor  D  activity:  1 ml of human  serum was  chromato- 
graphed on a 0.5  X  90 cm column containing Sephadex G-75, and the fractions 
eluting at a  volume corresponding to 25,000 mol wt were pooled and concen- 
trated by ultrafiltration to 1 ml. The pool was treated with DFP,  10  -8 M, for 
30 min at 30°C to inactivate the factor D present, and then dialyzed to remove 
the  DFP.  0.4-ml portions  of  1:5  dilutions  in  DGVB  ++ of  the  DFP-treated 
25,000 tool wt pool were exposed to trypsin in the final concentrations shown 
in Table I  for 30 sec at 37°C  in final reaction volumes of 0.45  ml DGVB  ++. 
The reaction was stopped by the addition of 25 t~g SBTI in 0.05 ml DGVB  ++, DOUGLAS  T.  FEARON~  K.  FRANK  AUSTEN,  AND  SHAUN  RUDDY  359 
TABLE I 
Trypsin-Inducibl*  Factor D  Activity in a Pool  of 25,000  Mol Wt Serum Proteins 
Trypsin added*  Factor D activity (Z) 
0  0.02 
1  0.21 
2  0.27 
4  0.32 
8  0.35 
* Each reaction mixture was neutralized with 50/zg/ml  SBTI before assay for factor D 
activity. A reaction mixture containing only 10 #g/trypsin/ml and 50/zg SBTI/ml did not 
generate factor D activity. 
and the reaction mixtures were assayed for factor D  activity by means of the 
effective molecule titration. Trypsin treatment did uncover factor D hemolytic 
activity. In another experiment, the maximal effect was observed with 10 #g 
trypsin/ml and an interaction time with the pool of serum proteins of 30-120 s 
at 37°C. 
In  order to demonstrate that  the trypsin-inducible activity represented a 
single protein, plasma was subjected to QAE Sephadex anion exchange chroma- 
tography and all fractions were screened for trypsin-inducible factor D activity. 
80  ml  of plasma  obtained  from freshly drawn  blood  collected into  hexadi- 
methrine (3.6 rag/10 ml blood) and EDTA (10 rag/10 ml blood) were dialyzed 
against  the  0.0035  M  PO4  starting  buffer at  4°C.  After  centrifugation the 
resulting supernate was applied to a 5-x 90-cm column containing QAE Sepha- 
dex in 0.0035  M  PO4,  and  the protein eluted with  a  gradient of increasing 
NaC1 concentration. The column fractions were assayed for factor B in micro- 
titer  plates,  for factor D  by  effective molecule  titrations,  and  for  trypsin- 
inducible factor D  activity. 0.4-ml portions of the 15-ml fractions were treated 
with trypsin, 10/~g/ml, in a final reaction volume of 0.5 ml for 30 sec at 37°C, 
and the reaction was stopped by the addition of 50/zg SBTI in0.1 mlDGVB  ++. 
0.5 ml of this reaction mixture was added to 5 X  l0  T  EAC43 and 0.03/~g factor 
B  in 0.5  ml DGVB  ++,  and  the effective molecule  titration of factor D  per- 
formed as described. Trypsin-inducible factor D  activity eluted at 7.5 mS, just 
preceding factor D  which eluted at 8.7 mS  (Fig. 3). The peaks of factor D  and 
trypsin-induced  factor D  activity  were  distinct  from  and  free  of  factor B 
activity which eluted at 10.3 mS. 
The fractions containing the trypsin-inducible factor D activity were pooled, 
concentrated to 5 ml by ultrafiltration, and applied to a  2.6-x 90-cm column 
containing Sephadex G-75. The trypsin-inducible factor D  activity was deter- 
mined as during the screening of the QAE Sephadex column; the active frac- 
tions were pooled, concentrated to 1 ml, and applied to a  0.5-x 90-cm column 
containing Sephadex G-75 which  had been calibrated with ovalbumin (45,000 360  PROPERDIN  FACTOR  D:  ACTIVE  SITE  AND  PRECURSOR  FORM 
mol wt),  chymotrypsinogen  (25,000 tool  wt), and ribonuclease A  (13,700 mol 
wt). Trypsin-inducible factor D  activity filtered at a volume corresponding to 
a tool wt of 25,000, and no factor D  activity independent of trypsin treatment 
was present  (Fig.  4).  Because of its function  and  size,  this  trypsin-inducible 
factor D  activity was designated "precursor factor  D." 
Participation of precursor factor D  in the generation of the CoVF-dependent 
C3 eonvertase and in cleavage of factor B:  Because factor  D  was  originally 
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FIO. 3. QAE Sephadex chromatography of human plasma showing the elution positions of 
trypsin-inducible factor D  activity (O--©), factor D  (•--$),  and factor B  ([3--[3). 
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FIO.  4. Ana]ytical Sephadex  G-75  gel filtration  of  trypsin-inducible  factor  D  activity 
showing the filtration volumes of factor D activity obtained with (• -- •  ) and without (O --O) 
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described as being required for the generation of the CoVF-dependent C3 con- 
vertase (6) and for the fluid phase C3b-dependent cleavage of factor B  (4), the 
ability of trypsin-activated precursor factor D  to fulfill the factor D  require- 
ments in these reactions was examined. 4 #g of the precursor factor D prepara- 
tion, isolated by QAE Sephadex chromatography and Sephadex G-75 gel filtra- 
tion with recycling and quantitated by Folin assay, were treated with buffer 
or 0.45/zg trypsin for 30 s at 37°C in a final reaction volume of 0.04 ml DGVB++; 
the reaction was stopped by the addition of 4.5/zg SBTI in 0.01 ml DGVB  ++. 
0.5 ml DGVB  ++ containing 5/zg CoVF and 10 #g factor B  was added to this 
reaction mixture,  and  incubation was  carried out  for 30 min  at  37°C.  The 
generation of the CoVF-dependent C3 convertase was measured by the addi- 
tion of 5 X  l0  T unsensitized sheep erythrocytes in 0.1 ml GVB-EDTA. 0.4 ml 
guinea pig serum was diluted 1:4 in GVB-EDTA, followed by incubation for 
60  rain  at  37°C.  The  complete  reaction  mixture  generated 0.39  hemolytic 
sites/cell, whereas no sites were generated when the precursor factor D  was 
not  trypsin-activated,  nor  when  precursor  factor D  was  omitted  from  the 
otherwise complete reaction mixture (Table II). 1.0/~g factor D, when assayed 
simultaneously, yielded 0.86 hemolytic sites/cell. 
To examine fluid phase cleavage of factor B, two 0.8-/zg samples of the pre- 
cursor factor D  preparation, with and without activation by 10 #g trypsin/ml 
followed by neutralization with 100/zg/ml SBTI, were interacted with 17/zg 
factor B and 2/~g C3b for 60 rain at 37°C in a final reaction volume of 0.03 ml 
DGVB  ++. Immunoelectrophorefic analysis (Fig. 5) revealed cleavage of factor 
B, with the appearance of a fragment of q,-mobility, occurring only when factor 
B  was  interacted  with  C3b  and  trypsin-activated  precursor  factor D.  No 
cleavage of factor B  occurred in reaction mixtures that included: C3b alone, 
C3b and buffer containing trypsin and SBTI, precursor factor D  not activated 
with trypsin, or trypsin-activated precursor factor D  in the absence of C3b. 
Effect of DFP on precursor factor D before and after activation by trypsin:  Two 
reaction mixtures, each containing 2.5  t~g of the precursor factor D  prepara- 
tion, were exposed either to buffer or DFP,  10  m M, for 30 re_in at 30°C in a 
final volume of 2 ml DGVB  ++. Mter dialysis to remove the DFP, 0.4-ml por- 
TABLE II 
Generation of the CoVF-Dependent C3 Convertase with Trypsin-Activated Precursor 
Factor D 
Additions to CoVF and  factor B  Indirect  lysis activity  (Z) 
u/~a 
Precursor factor D, trypsin-treated  0.39 
Precursor factor D  0.0! 
Trypsin, SBTI  0.00 
Factor D  0.86 362  PROPERDLN  FACTOR  D: ACTIVE  SITE AND  PRECURSOR  ]FOR~ 
FIG. 5. Immunoelectrophoretic analysis of  the  capacity  of  trypsin-activated  precursor 
factor D to induce cleavage of factor B in the presence of C3b. 
tions were interacted with 0.45 gg trypsin in 0.05 ml DGVB  ++ for 30 s at 37°C, 
followed by addition of 5 #g SBTI in 0.05 ml DGVB  ++. A parallel set of reac- 
tion  mixtures  containing  precursor  factor  D  were  initially  interacted  with 
trypsin  and  then  SBTI,  and  subsequently  exposed  to  either  buffer or  DFP. 
DFP treatment before trypsin activation of precursor factor D  resulted in no 
loss of hemolytic activity, whereas DFP  treatment after activation produced 
complete, irreversible inhibition  (Table III). 
DISCUSSION 
The  demonstration  that DFP  inhibits properdin  factor D  activity indicates 
that a  serine esterase is essential  for the generation  of the alternate pathway 
C3 convertases,  a situation analogous  to the role of CI  (20) in the formation  of 
the classical C3 convertase,  C4-2. The  nature of the active site of factor D  was 
established  by utilizing the generation  of the hemolytically  active cellular in- 
termediate,  EAC43B(D),  bearing the C3b-dependent  C3  convertase  (Fig.  I). 
The  intermediate  could not be formed  when  factor D  had been pretreated  with 
DFP  (Fig. 2). This evidence  of the enzymatic  nature  of factor D  is consistent 
with previous  studies revealing  that factor D  activity is undiminished,  subse- 
quent  to the formation  and decay  of the CoVF-dependent  C3 convertase  (23) 
and that less  than equimolar  amounts  are sufficient for maximal  generation  of 
this convertase  (24). 
The  definition of properdin  factor D  as a serine esterase prompted  a search 
for its  parent proenzyme  form. The physiologic activator of the precursor form 
of factor D  was unknown,  and trypsin was employed  for this purpose  because 
of its broad  proteolytic  activity  and  known  ability to activate  other  proen- DOUGLAS T.  FEARON, K. FRANK AUSTEN~ AND SHAUN RUDDY 
TABLE III 
Effect oJ DFP on Precursor Factor O before and after Activation  by Trypsin 
363 
Sequence of treatment of precursor  factor D  Factor D  activity (Z) 
u/ml 
Buffer, trypsin-SBTI  0.52 
DFP, trypsin-SBTI  0.48 
Trypsin-SBTI, buffer  0.50 
Trypsin-SBTI, DFP  0.00 
zymes, including Cls (22, 25). The first indication of the existence of trypsin- 
inducible factor D  activity was provided by analysis of the pool of 25,000 mo- 
wt serum proteins which had been pretreated with DFP (Table I); the general 
tion of new factor D  activity was dependent upon the interaction of the pool 
with  trypsin. Analysis of plasma  fractionated by QAE  Sephadex  anion ex- 
change chromatography (Fig. 3)  revealed a  single peak of trypsin-inducible 
factor D  activity just preceding and discrete from factor D, and independent 
of factor B. The failure of trypsin to elaborate factor D  activity in other frac- 
tions is consistent with the activity being derived from a single plasma protein. 
Filtration of the pool obtained from the QAE Sephadex chromatography on 
Sephadex G-75 further purified this protein, and refiltration with appropriate 
molecular markers established a  tool wt of 25,000  for this protein  (Fig. 4), 
similar to that previously reported for factor D  (26). 
That this plasma protein was indeed the precursor of factor D  was estab- 
lished by the criteria which had originally defined factor D: the ability to inter- 
act with CoVF and factor B  to generate the CoVF-dependent C3 convertase 
(6)  (Table II) and the capacity to induce cleavage of factor B in the presence 
of C3b (4, 26) (Fig. 5). In both reactions, the trypsin-treated protein exhibited 
factor D-like activity, whereas the untreated protein was inactive. Accordingly, 
this protein from which trypsin elaborated factor D activity, as assessed by the 
formation of the cell-bound C3b-dependent C3  convertase, the generation of 
the CoVF-dependent C3 convertase, and the cleavage of factor B, was desig- 
nated "precursor factor D." The additional finding of the DFP resistance of 
the protein in its precursor state, and the DFP sensitivity of its trypsin-acti- 
vated state  (Table III)  completed the analogy to the known plasma serine 
esterases, each of which is derived from a DFP-resistant proenzyme. 
Although there are compelling analogies between factor D  and CI as indi- 
cated by their corresponding enzymatic roles in the generation of the alternate 
and classical pathway C3  convertases, respectively, there are significant dis- 
tinctions between the two proteins. The mol wt of factor D  is less than that 
of the smallest known subunit of Ci, the 36,000 mol wt light chain of Cis (27) 
and Ci is unable to substitute for factor D  in its reactions. However, it is not 
inconceivable that these proteins have a common phylogenetic ancestor. 
The appearance  of active factor D  in  the  chromatographic separation of 364  PROPERDIN  FACTOR  D:  ACTIVE  SITE  AND  PRECURSOR  FORM 
plasma, despite avoidance of activation of both Hageman factor and its sub- 
strates and divalent cation-dependent enzymes, raises the question of whether 
a  portion of factor D  exists in an active state in plasma. This possibility is 
supported by the ability of CoVF to deplete C3 in vivo, despite the inability 
of CoVF to interact with precursor factor D  to generate the CoVF-dependent 
convertase in vitro as indicated by this study (Table II). Furthermore, cleav- 
age of factor B and C3 have been reported for a patient genetically deficient 
in  the  C3b  inactivator  (28),  although precursor factor D  is inactive in  the 
cleavage of factor B in the presence of C3b in vitro (Fig. 5). Whether naturally 
occurring plasma protein inhibitors control active factor D in a manner analo- 
gous to the effect of the Ci inhibitor on Ci is yet to be examined. 
Implicit in the identification of a precursor form of factor D is the existence 
of one or more plasma proteins responsible for its physiologic activation. That 
the nonphysiologic activation of precursor factor D  by trypsin was inefficient 
was  indicated  by  the  generation with  this  reaction  of  only one-eighth the 
hemolytic activity available  in  a  similar amount of factor D  isolated from 
plasma in its activated state (Table II). The inefficiency may be explained by 
the capacity of trypsin to inactivate factor D: incubation of 10 ~g trypsin/ml 
with active factor D preparations results in loss of factor D hemolytic activity 
with a  half-life of approximately 1 min at 37°C.  Properdin, the  186,000 tool 
wt  gamma  globulin  required  for  zymosan-induced  formation  of  the  C3b- 
dependent C3 convertase (29, 30) has been isolated in an apparent activated 
state, so that its introduction into serum resulted in cleavage of factor B and 
C3. Treatment of purified C3 and factor D with this form of properdin did not 
lead to cleavage of either factor, indicating that the primary effect of properdin 
was on plasma proteins other than C3 (31). Properdin, partially purified from 
an eluate of zymosan that had been incubated in serum (32) has recently been 
observed to participate in the activation of precursor factor D. 
SUMM_~R¥ 
The activity of properdin factor D  was measured by the generation of the 
hemolytically active  cellular  intermediate,  EAC43B(D),  bearing  the  C3b- 
dependent  alternate  pathway  C3  convertase.  Treatment  of  factor  D  with 
DFP prevented formation of EAC43B(D); thus, a  serine esterase is essential 
for the generation of the alternate pathway C3 convertase, a situation analo- 
gous to the role of Ci in the formation of the classical C3 convertase, C4-2. The 
definition of factor D  as a serine esterase prompted a search for its proenzyme 
form, and resulted in the chromatographic isolation from plasma of a  single 
peak of trypsin-inducible factor D  activity, distinct from activated factor D. 
Analytical gel filtration indicated an apparent tool wt of 25,000. This protein 
from which trypsin elaborated factor D  activity, as assessed by the formation 
of EAC43B(D),  the generation of the  CoVF-dependent C3  convertase,  and 
the cleavage of factor B  in the presence of C3b,  was designated "precursor DOUGLAS  T.  FEARON~  K.  FRANK  AUSTEN,  AND  SHAUN  RUDDY  365 
factor D."  The DFP  resistance  of precursor factor D,  and  the  susceptibility 
of its  trypsin-activated form to inactivation  by DFP  is analogous to the be- 
havior of other plasma serine esterases,  including C1. 
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